Form 8-K - Current report:
SEC Accession No. 0001564590-20-012109
Filing Date
2020-03-23
Accepted
2020-03-23 07:16:43
Documents
14
Period of Report
2020-03-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mygn-8k_20200321.htm   iXBRL 8-K 36448
2 EX-99.1 mygn-ex991_9.htm EX-99.1 15631
3 GRAPHIC gaic2g4ktpr0000001.jpg GRAPHIC 4299
  Complete submission text file 0001564590-20-012109.txt   189605

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mygn-20200321.xsd EX-101.SCH 5768
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mygn-20200321_lab.xml EX-101.LAB 18734
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mygn-20200321_pre.xml EX-101.PRE 11169
14 EXTRACTED XBRL INSTANCE DOCUMENT mygn-8k_20200321_htm.xml XML 3414
Mailing Address 320 WAKARA WAY SALT LAKE CITY UT 84108
Business Address 320 WAKARA WAY SALT LAKE CITY UT 84108 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 000-26642 | Film No.: 20733546
SIC: 2835 In Vitro & In Vivo Diagnostic Substances